Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 115

1.

Validation of a Molecular Risk Score for Prognosis of Patients With Acute Promyelocytic Leukemia Treated With All-trans Retinoic Acid and Chemotherapy-containing Regimens.

Hecht A, Doll S, Altmann H, Nowak D, Lengfelder E, Röllig C, Ehninger G, Spiekermann K, Hiddemann W, Weiß C, Hofmann WK, Nolte F, Platzbecker U.

Clin Lymphoma Myeloma Leuk. 2017 Dec;17(12):889-896.e5. doi: 10.1016/j.clml.2017.08.095. Epub 2017 Aug 15.

PMID:
28923666
2.

Mutations of Epigenetic Modifier Genes as a Poor Prognostic Factor in Acute Promyelocytic Leukemia Under Treatment With All-Trans Retinoic Acid and Arsenic Trioxide.

Shen Y, Fu YK, Zhu YM, Lou YJ, Gu ZH, Shi JY, Chen B, Chen C, Zhu HH, Hu J, Zhao WL, Mi JQ, Chen L, Zhu HM, Shen ZX, Jin J, Wang ZY, Li JM, Chen Z, Chen SJ.

EBioMedicine. 2015 Apr 12;2(6):563-71. doi: 10.1016/j.ebiom.2015.04.006. eCollection 2015 Jun.

3.

Internal tandem duplication of the FLT3 gene confers poor overall survival in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline-based chemotherapy: an International Consortium on Acute Promyelocytic Leukemia study.

Lucena-Araujo AR, Kim HT, Jacomo RH, Melo RA, Bittencourt R, Pasquini R, Pagnano K, Fagundes EM, Chauffaille Mde L, Chiattone CS, Lima AS, Ruiz-Argüelles G, Undurraga MS, Martinez L, Kwaan HC, Gallagher R, Niemeyer CM, Schrier SL, Tallman MS, Grimwade D, Ganser A, Berliner N, Ribeiro RC, Lo-Coco F, Löwenberg B, Sanz MA, Rego EM.

Ann Hematol. 2014 Dec;93(12):2001-10. doi: 10.1007/s00277-014-2142-9. Epub 2014 Jul 2.

PMID:
24981688
4.

Prognostic importance of expression of the Wilms' tumor 1 gene in newly diagnosed acute promyelocytic leukemia.

Hecht A, Nolte F, Nowak D, Nowak V, Reinwald M, Hanfstein B, Faldum A, Büchner T, Spiekermann K, Sauerland C, Weiss C, Hofmann WK, Lengfelder E.

Leuk Lymphoma. 2015;56(8):2289-95. doi: 10.3109/10428194.2014.990011. Epub 2015 Jan 21.

PMID:
25426668
5.

High expression of the Ets-related gene (ERG) is an independent prognostic marker for relapse-free survival in patients with acute promyelocytic leukemia.

Hecht A, Nowak D, Nowak V, Hanfstein B, Faldum A, Büchner T, Spiekermann K, Sauerland C, Lengfelder E, Hofmann WK, Nolte F.

Ann Hematol. 2013 Apr;92(4):443-9. doi: 10.1007/s00277-012-1648-2. Epub 2012 Dec 19. Erratum in: Ann Hematol. 2014 Aug;93(8):1447.

PMID:
23250622
6.

Clinical impact of galectin-3 in newly diagnosed t (15;17)(q22;q21)/PML-RARa acute promyelocytic leukemia treated with all-trans retinoic acid and arsenic trioxide-based regimens.

Gao N, Wang XX, Sun JR, Yu WZ, Li XZ.

Ann Hematol. 2017 May;96(5):711-718. doi: 10.1007/s00277-017-2948-3. Epub 2017 Feb 25.

PMID:
28238096
7.

High WT1 expression is an early predictor for relapse in patients with acute promyelocytic leukemia in first remission with negative PML-RARa after anthracycline-based chemotherapy: a single-center cohort study.

Yoon JH, Kim HJ, Kwak DH, Park SS, Jeon YW, Lee SE, Cho BS, Eom KS, Kim YJ, Lee S, Min CK, Cho SG, Kim DW, Lee JW, Min WS.

J Hematol Oncol. 2017 Jan 23;10(1):30. doi: 10.1186/s13045-017-0404-4.

8.

Expression of CD56 is an unfavorable prognostic factor for acute promyelocytic leukemia with higher initial white blood cell counts.

Ono T, Takeshita A, Kishimoto Y, Kiyoi H, Okada M, Yamauchi T, Emi N, Horikawa K, Matsuda M, Shinagawa K, Monma F, Ohtake S, Nakaseko C, Takahashi M, Kimura Y, Iwanaga M, Asou N, Naoe T; Japan Adult Leukemia Study Group.

Cancer Sci. 2014 Jan;105(1):97-104. doi: 10.1111/cas.12319. Epub 2014 Jan 9.

9.

A molecular risk score integrating BAALC, ERG and WT1 expression levels for risk stratification in acute promyelocytic leukemia.

Hecht A, Nowak D, Nowak V, Hanfstein B, Büchner T, Spiekermann K, Weiß C, Hofmann WK, Lengfelder E, Nolte F.

Leuk Res. 2015 Aug 20. pii: S0145-2126(15)30363-5. doi: 10.1016/j.leukres.2015.08.010. [Epub ahead of print]

PMID:
26344466
11.

Clinical significance of CD56 expression in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline-based regimens.

Montesinos P, Rayón C, Vellenga E, Brunet S, González J, González M, Holowiecka A, Esteve J, Bergua J, González JD, Rivas C, Tormo M, Rubio V, Bueno J, Manso F, Milone G, de la Serna J, Pérez I, Pérez-Encinas M, Krsnik I, Ribera JM, Escoda L, Lowenberg B, Sanz MA; PETHEMA; HOVON Groups.

Blood. 2011 Feb 10;117(6):1799-805. doi: 10.1182/blood-2010-04-277434. Epub 2010 Dec 8.

12.

All-trans retinoic acid with daunorubicin or idarubicin for risk-adapted treatment of acute promyelocytic leukaemia: a matched-pair analysis of the PETHEMA LPA-2005 and IC-APL studies.

Sanz MA, Montesinos P, Kim HT, Ruiz-Argüelles GJ, Undurraga MS, Uriarte MR, Martínez L, Jacomo RH, Gutiérrez-Aguirre H, Melo RA, Bittencourt R, Pasquini R, Pagnano K, Fagundes EM, Vellenga E, Holowiecka A, González-Huerta AJ, Fernández P, De la Serna J, Brunet S, De Lisa E, González-Campos J, Ribera JM, Krsnik I, Ganser A, Berliner N, Ribeiro RC, Lo-Coco F, Löwenberg B, Rego EM; IC-APL and PETHEMA and HOVON Groups.

Ann Hematol. 2015 Aug;94(8):1347-56. doi: 10.1007/s00277-015-2393-0. Epub 2015 May 15.

PMID:
25975975
13.
14.

Analysis of prognostic factors in newly diagnosed patients with acute promyelocytic leukemia: the APL92 study of the Japan Adult Leukemia Study Group (JALSG).

Asou N, Adachi K, Tamura U, Kanamaru A, Kageyama S, Hiraoka A, Omoto E, Akiyama H, Tsubaki K, Saito K, Kuriyama K, Oh H, Kitano K, Miyawaki S, Takeyama U, Yamada O, Nishikawa K, Takahashi M, Matsuda S, Ohtake H, Ohno R.

Cancer Chemother Pharmacol. 2001 Aug;48 Suppl 1:S65-71.

PMID:
11587370
15.

Clinical characteristics and outcome of childhood acute promyelocitic leukemia (APL) in Saudi Arabia: a multicenter SAPHOS leukemia group study.

Jastaniah W, Alsultan A, Al Daama S, Ballourah W, Bayoumy M, Al-Anzi F, Al Shareef O, Abrar MB, Al Sudairy R, Al Ghemlas I.

Hematology. 2018 Jul;23(6):316-323. doi: 10.1080/10245332.2017.1412380. Epub 2017 Dec 7.

PMID:
29212418
16.

BAALC and ERG expression levels are associated with outcome and distinct gene and microRNA expression profiles in older patients with de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study.

Schwind S, Marcucci G, Maharry K, Radmacher MD, Mrózek K, Holland KB, Margeson D, Becker H, Whitman SP, Wu YZ, Metzeler KH, Powell BL, Kolitz JE, Carter TH, Moore JO, Baer MR, Carroll AJ, Caligiuri MA, Larson RA, Bloomfield CD.

Blood. 2010 Dec 16;116(25):5660-9. doi: 10.1182/blood-2010-06-290536. Epub 2010 Sep 14.

17.

[Effect of all-trans retinoic acid on the newly diagnosed acute promyelocytic leukaemia: our experience].

Rolovitsh Z, Cholovitsh M, Elezovitsh I, Vidovitsh A, Radoshevitsh-Radojkovitsh N, Boshkovitsh D, Novak A, Basara N.

Srp Arh Celok Lek. 1995 Nov-Dec;123(11-12):279-85. Serbian.

PMID:
16296239
18.

Incidence, clinical features, and outcome of all trans-retinoic acid syndrome in 413 cases of newly diagnosed acute promyelocytic leukemia. The European APL Group.

De Botton S, Dombret H, Sanz M, Miguel JS, Caillot D, Zittoun R, Gardembas M, Stamatoulas A, Condé E, Guerci A, Gardin C, Geiser K, Makhoul DC, Reman O, de la Serna J, Lefrere F, Chomienne C, Chastang C, Degos L, Fenaux P.

Blood. 1998 Oct 15;92(8):2712-8.

19.

Arsenic trioxide and all-trans retinoic acid treatment for acute promyelocytic leukaemia in all risk groups (AML17): results of a randomised, controlled, phase 3 trial.

Burnett AK, Russell NH, Hills RK, Bowen D, Kell J, Knapper S, Morgan YG, Lok J, Grech A, Jones G, Khwaja A, Friis L, McMullin MF, Hunter A, Clark RE, Grimwade D; UK National Cancer Research Institute Acute Myeloid Leukaemia Working Group.

Lancet Oncol. 2015 Oct;16(13):1295-305. doi: 10.1016/S1470-2045(15)00193-X. Epub 2015 Sep 14.

PMID:
26384238
20.

Supplemental Content

Support Center